BRD2 and rectal neoplasm: From a genetic profile perspective, mutations in TP53 and KRAS, identified in ~70% and ~40% of rectal tumors [36,37], are associated with worse response to NAT, while mismatch repair deficiency tumors are overall associated with good response to NAT [38].